Singulair (Asthma) – Forecast and Market Analysis to 2023 Single User License : US$ 3495 Corporate User License : US$ Order this report by calling or Send an to with your contact details and questions if 1

Singulair (Asthma) – Forecast and Market Analysis to 2023 Researcher has released its new PharmaPoint Drug Evaluation report, “Singulair (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta- agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. Call Now | at 2

Singulair (Asthma) – Forecast and Market Analysis to 2023 The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline. Singulair, developed by Merck, is a CysLT1 receptor inhibitor, blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs to the family of Cys- LTs, which are mediators released from a variety of cells, including mast cells and eosinophils, and which bind to the family of CysLT receptors. Several studies have determined that there are higher concentrations of Cys-LTs in the airways and urine of asthmatics compared with non-asthmatic individuals. The production of CysLTs is increased in asthmatics, particularly during the early phase of bronchoconstriction that follows allergen challenge. Cys-LT signaling results in airway edema, smooth muscle contraction, and aberrant immune cell activity. Call Now | at 3

Singulair (Asthma) – Forecast and Market Analysis to 2023 Scope Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Singulair including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Singulair for the top eight countries from 2013 to Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Complete Report is asthma-forecast-and-market-analysis-to-2023.html. asthma-forecast-and-market-analysis-to-2023.html Call Now | at 4

Singulair (Asthma) – Forecast and Market Analysis to 2023 Reasons To Buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Asthma Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Singulair performance Obtain sales forecast for Singulair from in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia) Buy the copy of this Call Now | at 5

Singulair (Asthma) – Forecast and Market Analysis to 2023 About Us marketoptimizer.org is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. marketoptimizer.org also offers company data, country profiles, trends, information and analysis on the sector of your interest. Visit Follow Us: Call Now | 6